Jul 27, 2026 04:36PM
Jan 28, 2026 04:01PM
Jan 12, 2026 07:04AM
Jan 12, 2026 07:00AM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Dec 6, 2025 09:30AM Nurix reports 83% response rate for leukemia drug in phase 1 trial
Dec 6, 2025 09:30AM
Oct 28, 2025 06:42AM
Oct 22, 2025 07:28AM
Oct 22, 2025 06:00AM
Sep 17, 2025 07:01AM
Sep 17, 2025 07:00AM
Jul 9, 2025 04:01PM Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Jul 7, 2025 07:00AM
Apr 17, 2025 07:01AM
Apr 17, 2025 07:00AM
Apr 9, 2025 07:05AM
Apr 8, 2025 04:00PM
Mar 17, 2025 07:01AM
Mar 17, 2025 07:00AM Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Jan 28, 2025 04:00PM
Jan 13, 2025 07:00AM
Dec 22, 2024 04:00AM
Dec 21, 2024 10:00AM
Dec 19, 2024 07:01AM
Dec 19, 2024 07:00AM
Oct 11, 2024 04:00PM Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Jul 12, 2024 07:13AM
Jul 11, 2024 04:00PM
Apr 10, 2024 07:00AM
Mar 11, 2024 07:01AM
Mar 11, 2024 07:00AM
Feb 15, 2024 04:00PM
Jan 16, 2024 04:01PM Nurix Therapeutics (NRIX) Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Jan 16, 2024 04:01PM
Jan 8, 2024 07:02AM
Jan 8, 2024 07:00AM
Nov 1, 2023 04:01PM
Nov 1, 2023 04:01PM
Oct 12, 2023 04:01PM
Jul 13, 2023 04:01PM Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
Apr 13, 2023 04:01PM
Feb 9, 2023 04:15PM
Jan 9, 2023 08:36AM
Jan 9, 2023 08:35AM
Dec 15, 2022 04:02PM
Dec 15, 2022 04:01PM
Nov 10, 2022 09:00AM Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
Jul 7, 2022 04:05PM

328,337 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All